Welcome to our dedicated page for DENTSPLY SIRONA news (Ticker: XRAY), a resource for investors and traders seeking the latest updates and insights on DENTSPLY SIRONA stock.
DENTSPLY SIRONA Inc. (symbol: XRAY) stands as the world’s largest manufacturer of professional dental products and technologies. As a global total solutions provider, Dentsply Sirona empowers dental professionals to offer better, safer, and faster dental care. The company’s extensive portfolio includes leading positions in consumables, equipment, technology, and specialty products. Dentsply Sirona is committed to innovation and quality, reflected in its comprehensive end-to-end solutions offering, which spans well-known and established brands in the industry.
Dentsply Sirona emerged from a merger between Dentsply International and Sirona Dental Systems in 2016. Today, the company manufactures and markets a complete range of dental and oral health products, including dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation.
Recently, Dentsply Sirona has announced enhancements to its DS Core platform, a cloud-based solution supporting dental professionals throughout the entire treatment continuum. The platform now boasts improved patient communication tools, a unified ordering system, and support for additional data formats, making it easier for dental practices to collaborate with labs and service providers.
Financially, Dentsply Sirona maintains a robust presence in the dental industry, with significant revenue generated through third-party distributors and direct sales to labs, offices, and consumers. The company’s ongoing commitment to innovation is further demonstrated by its DS World Las Vegas event, an annual gathering that provides dental professionals with market-leading education, networking opportunities, and exposure to the latest dental technologies.
With its headquarters in Charlotte, North Carolina, Dentsply Sirona continues to shape the future of dentistry, striving to enhance patient care and advance dental practices through its unwavering dedication to quality and innovation. For more information on Dentsply Sirona and its products, visit the official website.
Dentsply Sirona (Nasdaq: XRAY) announced the repositioning of its Byte business model, emphasizing expanded in-person dentist oversight for treatments. The company aims to leverage Byte's direct-to-consumer (DTC) demand generation capabilities, enhance digital customer journey management, and improve customer service and marketing across its aligner portfolio. Dentsply Sirona will not reinstate at-home Byte Aligner Systems and Impression Kits but will continue to support existing non-contraindicated patients. The company will work with regulatory authorities to obtain necessary clearances before any market launch. CEO Simon Campion highlighted the company's commitment to quality, compliance, and broad access to care. Dentsply Sirona will present this strategy at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. Presentation materials and a webcast replay will be available on the company's investor website.
Dentsply Sirona (XRAY) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management team is scheduled to deliver their presentation on Wednesday, January 15, 2025, at 7:30 am PT (10:30 am ET).
Interested parties, including investors, will have access to both a live audio webcast and a webcast replay of the presentation through the Investors section of Dentsply Sirona's website at investor.dentsplysirona.com.
Dentsply Sirona (Nasdaq: XRAY) has announced a quarterly cash dividend declaration by its Board of Directors. The company will pay $0.16 per share of common stock, which indicates an annual rate of $0.64 per share. Shareholders who are holders of record as of December 27, 2024, will receive the dividend payment on January 10, 2025.
Dentsply Sirona (Nasdaq: XRAY) has announced its participation in the 7th Annual Evercore ISI HealthCONx Conference. The company's management will engage in a fireside chat discussion on December 5, 2024, at 8:20 am ET. Interested parties can access both the live audio webcast and replay through the Investors section of Dentsply Sirona's website at investor.dentsplysirona.com.
Dentsply Sirona (Nasdaq: XRAY) has appointed Herman V. Cueto as Interim Chief Financial Officer, effective immediately. Cueto brings over 20 years of experience in healthcare finance leadership. He will oversee the finance organization while the company conducts its search for a permanent CFO. CEO Simon Campion expressed confidence in Cueto's financial acumen, operational expertise, and understanding of the global healthcare sector to help execute strategic priorities during this transition period.
Dentsply Sirona (XRAY) reported Q3 2024 results with net sales of $951 million, up 0.5% year-over-year, with organic sales growth of 1.3%. The company posted a GAAP net loss of ($494) million, or ($2.46) per share, including a non-cash goodwill impairment charge of ($495) million. Adjusted EPS was $0.50, slightly up from $0.49 in Q3 2023. Due to market pressures in U.S. equipment and challenges with Byte, the company revised its FY24 outlook, now expecting organic sales decline of (3.5%) to (2.5%) and adjusted EPS of $1.82 to $1.86.
Dentsply Sirona (Nasdaq: XRAY) has announced a conference call and live webcast scheduled for October 25, 2024, at 9:00 am ET to discuss their Byte Aligner business. Interested participants can register for the call through the provided registration link. A replay of the webcast will be made available in the Investors section of the company's website after the call concludes.
Dentsply Sirona (XRAY) has voluntarily suspended sales and marketing of its Byte Aligners and Impression Kits while reviewing regulatory requirements in consultation with the FDA. The company reports preliminary Q3 2024 net sales of approximately $951 million with adjusted EPS expected between $0.49-$0.51. The company expects to record non-cash goodwill impairment charges of $450-$550 million for its Orthodontic Aligner Solutions and Implants & Prosthetic Solutions units, driven by state regulatory impacts on Byte business and weakened demand with competitive pricing pressures.
Dentsply Sirona, the world's largest manufacturer of professional dental products and technologies, has published its 2023 Sustainability Report. The report showcases strong progress in the company's sustainability strategy 'BEYOND: Taking Action for a Brighter World', with several goals achieved ahead of the 2025 timeframe.
Key highlights include:
- 47% reduction in Scope 1 and 2 GHG emissions intensity compared to 2019
- 29% reduction in water withdrawal intensity compared to 2019
- Enabled over 5.5 million smiles in 2023, contributing to more than 16.8 million smiles since 2021
- Achieved total average gender pay parity across the global workforce
- 54% of global hires in 2023 were diverse
- Hosted over 9,200 educational courses for customers in over 80 countries
- Achieved a top decile injury and illness prevention rate of 0.17
The company remains committed to its goal of Net Zero in Scope 1-3 carbon emissions by 2050 and continues to drive sustainable change within the dental industry through partnerships and initiatives.
Dentsply Sirona (Nasdaq: XRAY) has announced an upcoming investor conference call and live webcast scheduled for Thursday, November 7, 2024, at 8:30 am ET. The purpose of this event is to review the company's third quarter financial results.
Key details include:
- A presentation related to the call will be available on the Investors section of Dentsply Sirona's website.
- Investors can access the live webcast through the company's investor relations webpage.
- Those planning to participate in the call are required to register through a provided link.
- A webcast replay of the conference call will be made available on the company's website after the event.
This announcement demonstrates Dentsply Sirona's commitment to transparency and shareholder communication regarding its financial performance.